Patient advocacy is a vital component in assuring that roadblocks to optimal treatment do not prevent cancer patients from obtaining the help they deserve. Recently, a group from Parent Project Muscular Dystrophy presented the FDA [...]
The LRG helped fund research by the University of Pittsburgh Cancer Institute (UPCI) to screen a library of FDA-approved anticancer drugs that previously wouldn’t have been considered as a treatment for GIST. UPCI scientists have been surprised at [...]
The U.S. Food and Drug Administration (FDA) has asked ARIAD Pharmaceuticals, the manufacturer of Iclusig (ponatinib) to suspend marketing and sales of ponatinib because of the risk of life-threatening blood clots and severe narrowing of [...]
A recent report from the FDA reveals that Acetaminophen can cause serious skin reactions in rare occasions. Acetaminophen helps to reduce pain and fever, and is one of the most widely used medicines in the [...]
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
Family planning can be one of the hardest decisions patients with GIST make, but for Carolina Ponce Williams the decision was easy. At high risk for progression, Carolina longed to start a family. So she decided to adopt.
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
Treatment guidelines for GIST are established by experts to ensure that patients receive adequate care and appropriate therapies.
“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.
Concerns raised, FDA meets on ESAs. Concerns raised, FDA meets on ESAs. Erythropoetin stimulating agents (ESAs) promote the production of red blood cells by red blood stem cells.
